RBC Capital Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $84
Legend Biotech Price Target Maintained With a $84.00/Share by RBC Capital
RBC Capital Remains a Buy on Legend Biotech (LEGN)
Barclays Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $94
Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW) and Legend Biotech (LEGN)
Legend Biotech Analyst Ratings
Legend Biotech (LEGN) Gets a Buy From Barclays
Legend Biotech: Strong Market Position and Growth Potential Justify Buy Rating
TD Cowen Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $62
H.C. Wainwright Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $75
Legend Biotech Analyst Ratings
RBC Capital Keeps Their Buy Rating on Legend Biotech (LEGN)
Barclays Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $94
Morgan Stanley Maintains Legend Biotech(LEGN.US) With Buy Rating, Cuts Target Price to $80
Legend Biotech Analyst Ratings
Morgan Stanley Maintains Overweight on Legend Biotech, Lowers Price Target to $80
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN) and EyePoint Pharmaceuticals (EYPT)
Barclays Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $94
A Quick Look at Today's Ratings for Legend Biotech(LEGN.US), With a Forecast Between $75 to $95
HC Wainwright & Co. Maintains Buy on Legend Biotech, Raises Price Target to $75